Jim Huntington, PhD

Co-Founder & Chief Scientific Advisor

ApcinteX & Z Factor

Jim Huntington, PhD, is Chief Scientific Advisor of ApcinteX and Z Factor. He graduated in 1989 from the University of Kansas with Bachelor’s degrees in Chemistry and Mathematics. While an undergraduate, he worked as a Research Assistant in the Pharmaceutical Chemistry Department and at the Merck subsidiary InterX conducting chemical synthesis and in vitro and in vivo testing of prodrugs and prodrug-like enhancers of skin permeability. He subsequently worked as a Chemist at Alza Corporation in California, USA for three years evaluating compounds that enhance the electrotransport of drugs across the skin.

Jim obtained a PhD from Vanderbilt University in 1997 for work on the biophysical characterisation of members of the serpin family of proteins with Peter Gettins. His research on the serpins continued during a postdoc with Robin Carrell at the University of Cambridge, where he used X-ray crystallography to determine the mechanisms of serpin function and dysfunction. He was appointed Principal Investigator at the Cambridge Institute for Medical Research in 1999, University Reader in 2007 and Professor of Molecular Haemostasis in 2011.

Jim’s current research focuses on determining the structures of the molecular engines of blood coagulation, the Xase and prothrombinase complexes, using crystallography and single particle cryo-EM.

Jim has founded several biotech companies, including: XO1 (acquired by Janssen Pharmaceuticals, Inc., in 2015), SuperX and ReBalance in the field of thrombosis; ApcinteX in haemophilia; Z Factor to treat alpha-1-antitrypsin deficiency; SDS Therapeutics; and a reagents and services company, Cambridge ProteinWorks.

Read more about ApcinteX and Z Factor

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser